Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials
- PMID: 22467671
- PMCID: PMC3404714
- DOI: 10.1093/cid/cis274
Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials
Comment on
-
Excess deaths associated with tigecycline after approval based on noninferiority trials.Clin Infect Dis. 2012 Jun;54(12):1699-709. doi: 10.1093/cid/cis270. Epub 2012 Mar 30. Clin Infect Dis. 2012. PMID: 22467668 Free PMC article.
References
-
- US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. US Food and Drug Administration. 1 September 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm . Accessed 19 April 2012.
-
- Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834–44. - PubMed
-
- Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–71. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical